TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: episodes due to serotypes contained in the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response rates (delta Hamilton > or = 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak delivered voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak delivered current
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early satiation and postprandial fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intraoperative fentanyl requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time consumed per data value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seropositivity rates after booster vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titers (GMTs) post-primary and post-booster
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reactogenicity profiles
Endpoint domain: Adverse events/effects
Primary endpoint: Readmission to emergency department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vecuronium dose during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T4/T1r ratio upon arrival at the PARU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer false beliefs about nicotine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Probability of a correct response to nicotine is a cause of cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced probability of responding don't know
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: analgesic benefit of CPVB+SGB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophilic pulmonary inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inflammatory and oxidative stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical features of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in circulating EPCs and MPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in maximum urinary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in rTNSSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in iTNSSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in rTOSSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of cured lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unscheduled follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: neural cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse or aggravation of disease
Endpoint domain: Adverse events/effects
Primary endpoint: carbon monoxide transfer factor (Tlco)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life (QoL) physical component summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Flow-mediated vasodilatory response (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of OME after untreated AOM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual episodes of AOM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of AOM symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale for pain with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum bending force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bending rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of spermicide
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain response (crying and grimacing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic effectiveness of sucrose vs water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCr t1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADP t1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of voiding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum urine flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary tract infection relapse rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of ischemic cerebral lesions per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mean clinical attachment loss (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment sensitivity for H pylori detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central subfield macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine aminotransferase or aspartate aminotransferase elevations >3× upper limits of normal
Endpoint domain: Adverse events/effects
Primary endpoint: apoA‐I plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: times to fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quitting rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative plasma albumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median average time to intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest pulsoxymetric oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood to donate
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: fusion rate at 6 months postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Positive cultures from grafts
Endpoint domain: Adverse events/effects
Primary endpoint: VRS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cervical rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bioavailability of oral dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure admissions
Endpoint domain: Mortality/survival
Primary endpoint: rate of therapeutic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐therapeutic chalazion regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum HIV-RNA < 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SPS score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to neovascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic bone level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of ovulatory cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: peak E2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite primary efficacy endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in incontinence frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Impression of Improvement in Incontinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caries arrest rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Correlation of lymph node histology with grade and extent of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knowledge of bipolar disorder (assessed with OBQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of weeks well
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospital for Special Surgery (HSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic torque measurements during extension and flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary levels of oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of ICD shocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety profile according to Ocular Surface Disease Index
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalizations avoided
Endpoint domain: Mortality/survival
Primary endpoint: Deaths avoided
Endpoint domain: Mortality/survival
Primary endpoint: day and night symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tpe interval during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: need of rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of oxygen in arterial blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma neutrophil elastase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cumulative fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyperchloremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Light touch at 3 points of the feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement speed during vigilance tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+/CD8+ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transferrin, pre-albumin, albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: First flatus time after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum analyte concentration in the plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substantial behavioral gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substantial cognitive gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to antimanic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths due to transplant-related causes
Endpoint domain: Mortality/survival
Primary endpoint: Mean retinal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oocyte maturity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gonadotropin consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: severe ovarian hyper‐stimulation syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of menstrual migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of frovatriptan
Endpoint domain: Adverse events/effects
Primary endpoint: CAARS Total Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically active disease detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of RBV dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBV-induced hemolysis
Endpoint domain: Adverse events/effects
Primary endpoint: Trough FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in QALYs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean difference in total cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Burden of illness due to herpes zoster
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postherpetic neuralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of herpes zoster
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ischemia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medication changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Re-intubation within 48 hours after extubation
Endpoint domain: Mortality/survival
Primary endpoint: Success at the first SBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in written expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in listening comprehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who survived with a functioning graft
Endpoint domain: Mortality/survival
Primary endpoint: Mean error of MRSV calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Myalgic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body protein breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-body protein turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 21-day mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression of meniscal extrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: extent of bronchiectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global CT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-captopril ARR(ARC) cut-off value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Renal medullary oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ipsilateral motor cortex activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor cortex activation lateralization index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of QFT positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of MTB infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mitral valve gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in pulmonary artery systolic pressure (PASP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in information literacy skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone-only recurrence-free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: ulcer-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prealbumin and retinol‐binding protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulse oxygen saturation after preoxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Minimum SpO2 during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severe hypoxemic events (SpO2 < 80%)
Endpoint domain: Adverse events/effects
Primary endpoint: everyday mood stability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: correct responding following exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic gastroesophageal reflux detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chest discomfort frequency
Endpoint domain: Adverse events/effects
Primary endpoint: S-100beta peak values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma DPP-4 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of intact GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: opioid use rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTPDase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of parenteral analgesic injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic anal stenosis requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: mean heart rate at AF onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of PAF episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 m sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: birth of a healthy child
Endpoint domain: Mortality/survival
Primary endpoint: multiple pregnancy rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mobilization timing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinical decision-making performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-technical skills performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved β‐cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean phenylephrine dose administered prior to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean umbilical artery and vein blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of complicated surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of femoral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment responder status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue ketorolac consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to initiate CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical exertion during procedure
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 7-year overall survival (OS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in symptoms and lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hormone withdrawal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of systemic withdrawal reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Total case fatality
Endpoint domain: Mortality/survival
Primary endpoint: clearance or marked improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status